Olutasidenib 150 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 150 mg

Reference Brands: Rezlidhia (USA)

Category: Oncology Cancer Care

Olutasidenib is a Oncology Cancer Care product available as Capsules in strengths 150 mg. It corresponds to the reference brand Rezlidhia (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Olutasidenib, marketed under the brand name Rezlidhia, is an oral targeted anticancer therapy used for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. It belongs to a class of precision oncology drugs designed to address the underlying genetic drivers of certain cancers.

Olutasidenib works by selectively inhibiting the mutant IDH1 enzyme, which is responsible for producing the oncometabolite 2-hydroxyglutarate (2-HG). Elevated levels of 2-HG disrupt normal cellular differentiation and contribute to the development and progression of leukemia. By reducing 2-HG production, olutasidenib helps restore normal cell maturation and suppress the growth of malignant leukemic cells.

Administered orally, Rezlidhia offers a convenient treatment option for patients who have limited therapeutic alternatives after disease relapse or resistance to prior therapies. The drug represents an important advancement in personalized cancer treatment, as it is specifically indicated for patients whose tumors harbor an IDH1 mutation. Through its targeted mechanism of action, olutasidenib provides a focused approach to managing AML while minimizing effects on non-mutated cells, supporting improved disease control and patient outcomes.